MX2024002822A - Composicion farmaceutica y uso de la misma. - Google Patents

Composicion farmaceutica y uso de la misma.

Info

Publication number
MX2024002822A
MX2024002822A MX2024002822A MX2024002822A MX2024002822A MX 2024002822 A MX2024002822 A MX 2024002822A MX 2024002822 A MX2024002822 A MX 2024002822A MX 2024002822 A MX2024002822 A MX 2024002822A MX 2024002822 A MX2024002822 A MX 2024002822A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
disease mediated
present
insertion mutation
Prior art date
Application number
MX2024002822A
Other languages
English (en)
Spanish (es)
Inventor
Qing Li
Huibing Luo
Original Assignee
Shanghai Allist Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Co Ltd filed Critical Shanghai Allist Pharmaceuticals Co Ltd
Publication of MX2024002822A publication Critical patent/MX2024002822A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002822A 2021-09-10 2022-04-11 Composicion farmaceutica y uso de la misma. MX2024002822A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2021/117692 WO2023035223A1 (zh) 2021-09-10 2021-09-10 药物组合物及其用途
PCT/CN2022/086053 WO2023035611A1 (en) 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
MX2024002822A true MX2024002822A (es) 2024-05-03

Family

ID=85507161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002822A MX2024002822A (es) 2021-09-10 2022-04-11 Composicion farmaceutica y uso de la misma.

Country Status (10)

Country Link
US (1) US20240366600A1 (OSRAM)
EP (1) EP4398909A4 (OSRAM)
JP (1) JP2024533423A (OSRAM)
KR (1) KR20240074779A (OSRAM)
CN (1) CN117957000A (OSRAM)
AU (1) AU2022341942A1 (OSRAM)
CA (1) CA3231192A1 (OSRAM)
IL (1) IL311331A (OSRAM)
MX (1) MX2024002822A (OSRAM)
WO (2) WO2023035223A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
CN119278041A (zh) * 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116478138A (zh) * 2023-04-21 2023-07-25 江苏艾力斯生物医药有限公司 一种甲磺酸伏美替尼原料药的结晶方法
CN116893086A (zh) * 2023-04-28 2023-10-17 江苏艾力斯生物医药有限公司 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法
CN117547536A (zh) * 2023-11-15 2024-02-13 江苏艾力斯生物医药有限公司 一种药物组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN107163027B (zh) * 2016-03-07 2019-11-05 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用

Also Published As

Publication number Publication date
WO2023035223A1 (zh) 2023-03-16
AU2022341942A1 (en) 2024-05-02
EP4398909A1 (en) 2024-07-17
CA3231192A1 (en) 2023-03-16
US20240366600A1 (en) 2024-11-07
KR20240074779A (ko) 2024-05-28
IL311331A (en) 2024-05-01
WO2023035611A1 (en) 2023-03-16
CN117957000A (zh) 2024-04-30
JP2024533423A (ja) 2024-09-12
EP4398909A4 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2022000143A (es) Metodos novedosos.
WO2015184145A8 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112016028641A2 (pt) ?método para tratar câncer?
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
AR078170A1 (es) Metodos para el tratamiento de tumores cerebrales
ES2164899T3 (es) Uso de alcaloides de la clase lamellarina en metodos de tratamiento.
BR112015012497A2 (pt) combinações farmacêuticas
MX2024006168A (es) Composicion farmaceutica y uso de la misma.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2025002967A (es) Composicion farmaceutica y uso de la misma
UY31826A (es) Compuesto peptídico y su uso
AR049136A1 (es) Composicion y metodo con irinotecan (cpt-11) y un inhibidor del egfr,como erlotinib